002004:SZSEHuapont Life Sciences Co.,Ltd. Analysis

Huapont Life Sciences is trading at CNY 4.43, comfortably above its 20‑day (4.27) and 50‑day (4.32) moving averages but still below the 200‑day average (4.90), signaling a short‑term bounce within a longer‑term bearish backdrop. The MACD has turned bullish (histogram +0.026) while the RSI sits at a neutral 57, suggesting limited upside momentum. Valuation is mixed: a PE of 12.7 and PB of 0.84 point to relative cheapness, yet the DCF‑derived fair value of 3.83 is well under the current price, indicating potential overvaluation on cash‑flow grounds. The company boasts an eye‑catching dividend yield of 10.16% with a payout ratio of 57%, supported by solid operating cash flow, but its debt‑to‑equity of 46% and net debt of ~CNY 3.1 bn raise leverage concerns. Volatility is high (30‑day ≈ 29%) and the max drawdown of 33% underscores downside risk, though the beta is extremely low (~0.04) and the market sentiment is in “Extreme Greed” mode.